CC-115 in newly diagnosed MGMT unmethylated glioblastoma in the individualized screening trial of innovative glioblastoma therapy (INSIGhT): A phase II randomized Bayesian adaptive platform trial Meeting Abstract


Authors: Rahman, R.; Trippa, L.; Fell, G.; Lee, E.; Arrillaga-Romany, I.; Touat, M.; McCluskey, C.; Brunno, J.; Gaffey, S.; Drappatz, J.; Lassman, A.; Galanis, E.; Ahluwalia, M.; Colman, H.; Nabors, L.; Hepel, J.; Elinzano, H.; Schiff, D.; Chukwueke, U.; Beroukhim, R.; Nayak, L.; McFaline-Figueroa, J.; Batchelor, T.; Rinne, M.; Kaley, T.; Lu-Emerson, C.; Bi, W. L.; Arnaout, O.; Haas-Kogan, D.; Tanguturi, S.; Cagney, D.; Aizer, A. A.; Welch, M.; Doherty, L.; Lavallee, M.; Fisher-Longden, B.; Dowling, S.; Geduldig, J.; Watkinson, F.; Santagata, S.; Meredith, D.; Chiocca, E. A.; Reardon, D.; Ligon, K.; Alexander, B.; Wen, P.
Abstract Title: CC-115 in newly diagnosed MGMT unmethylated glioblastoma in the individualized screening trial of innovative glioblastoma therapy (INSIGhT): A phase II randomized Bayesian adaptive platform trial
Meeting Title: 25th Virtual Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Journal Title: Neuro-Oncology
Volume: 22
Issue: Suppl. 2
Meeting Dates: 2020 Nov 19-21
Meeting Location: Virtual Conference
ISSN: 1522-8517
Publisher: Oxford University Press  
Date Published: 2020-11-01
Start Page: ii43
End Page: ii44
Language: English
ACCESSION: WOS:000590061300179
PROVIDER: wos
DOI: 10.1093/neuonc/noaa215.178
Notes: Meeting Abstract: CTNI-11 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Thomas Kaley
    154 Kaley